title: Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.
abstract: Ribonucleic acid (RNA) in its many facets of structure and function is becoming more fully understood, and, therefore, it is possible to design and use RNAs as valuable tools in molecular biology and medicine. Understanding of the role of RNAs within the cell has changed dramatically during the past few years. Therapeutic strategies based on non-coding regulatory RNAs include RNA interference (RNAi) for the silencing of specific genes, and microRNA (miRNA) modulations to alter complex gene expression patterns. Recent progress has allowed the targeting of therapeutic RNAi to the heart for the treatment of heart failure, and we discuss current strategies in this field. Owing to the peculiar biochemical properties of small RNA molecules, the actual therapeutic translation of findings in vitro or in cell cultures is more demanding than with small molecule drugs or proteins. The critical requirement for animal studies after pre-testing of RNAi tools in vitro likewise applies for miRNA modulations, which also have complex consequences for the recipient that are dependent on stability and distribution of the RNA tools. Problems in the field that are not yet fully solved are the prediction of targets and specificity of the RNA tools as well as their tissue-specific and regulatable expression. We discuss analogies and differences between regulatory RNA therapy and classical gene therapy, since recent breakthroughs in vector technology are of importance for both. Recent years have witnessed parallel progress in the fields of gene-based and regulatory RNA-based therapies that are likely to significantly expand the cardiovascular therapeutic repertoire within the next decade.
authors.affiliation: Department of Cardiology and Pneumology, Charité Centrum 11, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D-12200 Berlin, Germany. wolfgang.poller@charite.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Poller
authors.forename: Roger
authors.initials: R
authors.lastname: Hajjar
authors.forename: Heinz-Peter
authors.initials: HP
authors.lastname: Schultheiss
authors.forename: Henry
authors.initials: H
authors.lastname: Fechner
mesh_terms: D000818:Animals; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D005822:Genetic Vectors; D006333:Heart Failure / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism*; D034622:RNA Interference; D038621:Regulatory Sequences, Ribonucleic Acid; D016896:Treatment Outcome
chemical_list: D035683:MicroRNAs; D038621:Regulatory Sequences, Ribonucleic Acid